The reiteration of a Buy rating by Needham analyst Ami Fadia on Jazz Pharmaceuticals (JAZZ) and maintaining a $226 price target indicates a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the confidence of the analyst in the company's performance and potential growth.